___

• 1. Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid” : epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26:3063-3072.2. Volante M, Gatti G, Papotti M. Classification of lung neuroendocrine tumors: lights and shadows. Endocrine. 2015; 50(2): 315-319.3. Hendifar AE, Marchevsky AM, Tuli R. Neuroendocrine Tumors of the Lung: Current Challenges and Advances in the Diagnosis and Management of Well- Differenriated Disease. Journal of Thoracic Oncology 2016; 3: 425-436. 4. Rice TW, Rodriguez RM, Light RW. The superior vena cava syndrome: clinical characteristics and evolving etiology. Medicine (Baltimore). 2006;85(1):37.5. Yellin A, Rosen A, Reichert N, Lieberman Y. Superior vena cava syndrome. The myth--the facts. Am Rev Respir Dis. 1990;141(5 Pt 1):1114. 6. Schraufnagel DE, Hill R, Leech JA, Pare JA. Superior vena caval obstruction. Is it a medical emergency? Am J Med. 1981;70(6):1169.7. Friedman T, Quencer KB, Kishoer SA, Winokur RS, Madoff DC. Malignant Venous Obstruction: Superior Vena Cava Syndrome and Beyond. Semin Intervent Radiol. 2017;34(4):398.8. Kalra M, Sen I, Gloviczki P. Endovenous and Operative Treatment of Superior Vena Cava Syndrome. Surg Clin North Am. 2018;98(2):321.9. García Mónaco R, Bertoni H, Pallota G, Lastiri R, Varela M, Beveraggi EM, Vassallo BC. Use of self-expanding vascular endoprostheses in superior vena cava syndrome. Eur J Cardiothorac Surg. 2003;24(2):208. 10. Yu JB, Wilson LD, Detterbeck FC (2008) Superior Vena Cava Syndrome: a proposed classification system and algorithm for management. J Thorac Oncol 3(811–814):8.Wan JF, Bezjak A. Superior vena cava syndrome. Hematol Oncol Clin N Am 2010;24:501-13.11. Mesko SM, Rosenthal KJ, Boasberg PD, Omid H. BRAF-Targeted Therapy to Treat Superior Vena Cava Syndrome in Patient with Metastatic Cancer. J Clin. Oncol. 2015;33:101-103. 12. Wan JF, Bezjak A. Superior vena cava syndrome. Hematol Oncol Clin N Am 2010;24:501-13.13. Rowell NP, Gleeson FV. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus. Cochrane Database Syst Rev 2001;CD001316.14. Armstrong BA, Perez CA, Simpson JR, Hederman MA (1987) Role of irradiation in the management of superior vena cava syndrome. Int J Radiat Oncol Biol Phys 13:531–539.15. Yellin A, Rosen A, Reichert N, Lieberman Y (1990) Superior vena cava syndrome. The myth–the facts. Am Rev Respir Dis 141:1114–1118. doi:10.1164/ajrccm/141.5_Pt_1.1114.16. Nicholson AA, Ettles DF, Arnold A, Greenstone M, Dyet JF (1997) Treatment of malignant superior vena cava obstruction: metal stents or radiation therapy. J Vasc Interv Radiol 8:781–788.17. Mose S, Stabik C, Eberlein K, Ramm U, Bottcher HD, Budischewski K (2006) Retrospective analysis of the superior vena cava syndrome in irradiated cancer patients. Anticancer Res 26:4933–4936.18. Ostler PJ, Clarke DP, Watkinson AF, Gaze MN (1997) Superior vena cava obstruction: a modern management strategy. Clin oncol (R Coll Radiol) 9:83–89 Parish JM, Marschke RF Jr, Dines DE, Lee RE (1981) Etiologic considerations in superior vena cava syndrome. Mayo Clin Proc 56:407–413.19. Davenport D, Ferree C, Blake D, Raben M (1978) Radiation therapy in the treat ment of superior vena caval obstruction. Cancer 42:2600–2603 de Jager CP, Rutten MJ, Lips DJ (2013) “Benign” superior vena cava syndrome. Intensive Care Med 39:572–573.20. Straka C, Ying J, Kong FM et al. Review of evolving etiologies, implications and treatment strategies for the superior vena cava syndrome. SpringerPlus (2016) 5:229.21. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer. Version 1.2016.22. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology:Neuroendocrine and Adrenal Tumors, Version 2.2018.23. Martins SJ, Pereira JR. Clinical factors and survival in non-small cell lung cancer. Am J Clin Oncol 1999; 22:453-7